Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-08-23FDA Approved: XANAX XR — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for XANAX XR (alprazolam) filed by Viatris Specialty LLC.
-
FDA approval · 2011-08-23FDA Approved: ALPRAZOLAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for alprazolam from Mylan Pharmaceuticals Inc., affecting the generic product's labeling.
-
FDA label_change · 2011-08-22FDA Approved: ALPRAZOLAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for alprazolam submitted by Aurobindo Pharma Limited.
-
FDA approval · 2011-07-27FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride (paroxetine) from Zydus Lifesciences Limited under an ANDA.
-
FDA approval · 2011-06-20FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for LYRICA (pregabalin) submitted by Parke-Davis Div of Pfizer Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-06-17Clinical Trial Update: Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
This completed clinical trial evaluated changes in metabolic parameters in patients with major depressive disorder, generalized anxiety diso…
-
CLINICAL_TRIALS trial_result · 2011-06-10Clinical Trial Update: Escitalopram in Patients With Generalized Anxiety Disorder [Phase 4]
Phase 4 clinical trial update showing results for escitalopram in adults with Generalized Anxiety Disorder; the study has completed and resu…
-
FDA approval · 2011-06-07FDA Approved: ALPRAZOLAM — Original Application (Aurobindo Pharma Limited)
FDA approved a generic alprazolam product from Aurobindo Pharma Limited under an Original Application (ANDA).
-
FDA approval · 2011-06-01FDA Approved: ALPRAZOLAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Alprazolam from Mylan Pharmaceuticals, authorizing a generic alprazolam product. The approva…
-
CLINICAL_TRIALS trial_result · 2011-05-19Clinical Trial Update: AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD) [Phase 2]
A Phase 2 proof-of-concept trial of AZD7325 in generalized anxiety disorder has completed, with results posted in 2011.
-
FDA approval · 2011-05-12FDA Approved: LEXAPRO — Supplemental Application (Allergan, Inc.)
FDA has approved a supplemental application for Lexapro (escitalopram) submitted by Allergan, Inc.
-
CLINICAL_TRIALS research · 2011-05-12Clinical Trial Update: Mechanisms of Sleep Disturbance in Children With Generalized Anxiety Disorder (GAD)
This clinical trial investigates the mechanisms behind sleep disturbance in children with generalized anxiety disorder.
-
FDA approval · 2011-05-06FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Dr.Reddys Laboratories Inc)
FDA approved the original ANDA for Venlafaxine hydrochloride by Dr. Reddy's Laboratories Inc, enabling a generic version of this antidepress…
-
FDA approval · 2011-04-14FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the original ANDA for venlafaxine hydrochloride from Zydus Pharmaceuticals USA Inc., authorizing a generic version of the antid…
-
FDA approval · 2011-04-14FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's original ANDA for venlafaxine hydrochloride, a generic antidepressant.
-
FDA approval · 2011-04-12FDA Approved: CYMBALTA — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Cymbalta (duloxetine hydrochloride) submitted by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2011-04-06Clinical Trial Update: A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder [Phase 3]
Phase 3 trial evaluating efficacy and safety of Saredutant in Generalized anxiety disorder completed in North America.
-
CLINICAL_TRIALS trial_result · 2011-04-05Clinical Trial Update: Generalized Anxiety Disorder Adjunct Study [Phase 3]
Phase 3 trial results for an adjunctive therapy in generalized anxiety disorder have been completed and posted.
-
CLINICAL_TRIALS trial_result · 2011-03-10Clinical Trial Update: Psychodynamic Internet Treatment Versus Cognitive Behavioral Therapy (CBT) for Generalized Anxiety Disorder [NA]
This is a completed clinical trial comparing psychodynamic internet treatment with cognitive behavioral therapy for Generalized Anxiety Diso…
-
FDA approval · 2011-03-04FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride from Zydus Lifesciences Limited.
-
CLINICAL_TRIALS trial_result · 2011-01-31Clinical Trial Update: Study Of Generalized Anxiety Disorder [Phase 2]
This document reports a completed Phase 2 clinical trial sponsored by GlaxoSmithKline evaluating an investigational compound for generalized…
-
FDA approval · 2011-01-30FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Paroxetine hydrochloride by Zydus Lifesciences Limited, indicating an update to the labeling or …
-
CLINICAL_TRIALS trial_result · 2011-01-27Clinical Trial Update: The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form [Phase 3]
Phase 3 clinical trial evaluating Gamisoyosan for generalized anxiety disorder has completed, comparing different dosage forms.
-
FDA approval · 2010-12-21FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for buspirone hydrochloride filed by Aurobindo Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2010-12-17Clinical Trial Update: Duloxetine for the Treatment of Generalized Anxiety Disorder [Phase 3]
Phase 3 trial results for duloxetine in generalized anxiety disorder have been completed and results posted.